This program has been designed to improve the diagnosis, pharmacologic treatment and management of patients with chronic liver disease. The current data is highlighted to support effective and efficient patient-centered care. Attendees will gain the ability to utilize medical knowledge and research to provide quality, evidence-based care and to enhance interdisciplinary collaboration to improve health outcomes.Lisa M.

This program will describe the molecular mechanisms and rationale for novel systemic therapy agents targeting signaling pathways and immune mechanisms that have been recently approved for the treatment of hepatocellular carcinoma. The program will also cover the roles of new agents in the current AASLD guidelines for treatment of hepatocellular carcinoma.Jessica Zucman-Rossi Augusto Villanueva Augusto Villanueva is Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York).

This program will provide practicing clinicians with an update on recent changes in the epidemiology of alcoholic liver disease, advances in understanding of its pathophysiology and the impact of social policies on alcohol use disorders. The program will then present advances in the treatment of alcohol abuse and alcoholic liver disease, including novel models of multidisciplinary care for these patients.Jessica L. Mellinger Ian Gilmore Robert Weinrieb Vijay Shah

This lecture will examine the intersection of hepatobiliary neoplasia and liver transplantation to highlight what is currently working well, including liver transplantation for early stage hepatocellular carcinoma and hilar cholangiocarcinoma, as well as less common indications such as euroendocrine tumors. The speaker will highlight continued challenges, particularly related to overall disease burden, organ availability and allocation policy, and transplantation for more advanced tumors.

The goal of this program is to highlight the hepatic manifestations of various diseases endemic or epidemic in the Tropics. These diseases include viral A and E hepatitis; hepatic manifestations of viral epidemics like Dengue, SARS, and Zika virus; bacterial infections like typhoid; and parasitic diseases like malaria.Kenneth Sherman Harshad Devarbhavi Maria Cassia Mendes Edna Strauss Robert Gish Robert G. Gish, MD AGAF, FAST, FAASLD is currently an Adjunct Professor of Medicine at the University of Nevada Schools of Medicine in Las Vegas and in Reno.

This activity will provide updates and practical guidance for care providers dealing with 3 common and or difficult to manage conditions. The knowledge will improve practitioner's performance as care providers and will improve patient outcomes.Cynthia Levy Cynthia Levy, MD, FAASLD is a Professor of Medicine in the Division of Digestive Health and Liver Diseases and is the Associate Director of the Schiff Center for Liver Diseases at the University of Miami. She was awarded the Arthur Hertz Endowed Chair in Liver Diseases. Dr. Levy received her M.D.

Hans Clevers, MD, PhD, will describe his groundbreaking research in the development of organoid technology and how it can be applied to liver and biliary disease. His lecture will focus on organoids developed from bile duct cells and hepatocytes, and applications for disease modeling in cancer, hereditary disease and regenerative medicine strategies.Hans Clevers

This half-day program provides an overview of both current and emerging therapies for common liver diseases. Additionally, it will enhance knowledge around diagnostics and highlight the roles of collaborating professionals.Yuko Kono John E. Eaton Dr. John Eaton is a transplant Hepatologist with a clinical and research focus on cholestatic liver diseases with an emphasis on primary sclerosing cholangitis (PSC) and related comorbid conditions. His clinical practice involves seeing a large volume of patients with PSC and PSC complicated by cholangiocarcinoma. Dr.

Yanling Ma, Olga V. Belyaeva, Philip M. Brown, Koji Fujita, Katherine Valles, Suman Karki, Ynto S. de Boer, Christopher Koh, Yanhua Chen, Xiaomeng Du, Samuel K. Handelman, Vincent Chen, Elizabeth K. Speliotes, Cara Nestlerode, Emmanuel Thomas, David E. Kleiner, Joseph M. Zmuda, Arun J. Sanyal, (for the Nonalcoholic Steatohepatitis Clinical Research Network), Natalia Y. Kedishvili, T. Jake Liang, Yaron Rotman – 11 November 2018 – Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease.

John A. Geha, Joseph D. Geha, Christine A. O’Mahony, Ronald T. Cotton, Thao N. Galvan, Abbas Rana, John A. Goss – 11 November 2018